Skip to main content

Targretin Disease Interactions

There are 7 disease interactions with Targretin (bexarotene).

Moderate

Bexarotene (applies to Targretin) cataracts

Moderate Potential Hazard, Moderate plausibility.

The use of bexarotene may cause new cataracts or worsening of previous cataracts. It is recommended to monitor closely for the development of any visual difficulties and to have an appropriate ophthalmologic evaluation. Exercise caution when using this agent in patients with a history of cataracts.

References

  1. (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals
Moderate

Bexarotene (applies to Targretin) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

The use of bexarotene may cause hypoglycemia in diabetic patients. It is recommended to measure baseline blood glucose levels and to keep monitoring them closely during treatment. Exercise caution when using this agent in diabetic patients.

References

  1. (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals
Moderate

Bexarotene (applies to Targretin) hyperlipidemia

Moderate Potential Hazard, Moderate plausibility.

The use of bexarotene may cause elevations in lipids. It is recommended to monitor lipid levels closely and to obtain a fasting blood lipid reading at baseline and weekly until lipid response to the drug is established. Exercise caution when using this agent in patients with hyperlipidemia.

References

  1. (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals
Moderate

Bexarotene (applies to Targretin) hypothyroidism

Moderate Potential Hazard, Moderate plausibility.

The use of bexarotene may cause hypothyroidism. It is recommended to consider thyroid hormone supplementation in patients with hypothyroidism, to obtain baseline thyroid function tests, and to closely monitor patients during treatment.

References

  1. (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals
Moderate

Bexarotene (applies to Targretin) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

In vitro studies suggest that cytochrome P450 3A4 is the major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative metabolites may be glucuronidated. It is recommended to monitor for signs of toxicity due to increased drug exposure if bexarotene is used in patients with hepatic impairment as these patients are expected to have a decreased drug clearance.

References

  1. (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals
Moderate

Bexarotene (applies to Targretin) neutropenia

Moderate Potential Hazard, Moderate plausibility.

The use of bexarotene causes neutropenia. Neutropenia is reversible after dose reduction or discontinuation of treatment. Care should be exercised in patients at risk. It is recommended to obtain complete blood counts at baseline and periodically during treatment.

References

  1. (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals
Moderate

Bexarotene (applies to Targretin) pancreatitis

Moderate Potential Hazard, Moderate plausibility.

Pancreatitis, including a fatal case, has occurred in patients receiving bexarotene. It is recommended to monitor for pancreatitis and to interrupt treatment if pancreatitis is suspected. Close monitoring is recommended in patients who have risk factors for pancreatitis, such as high alcohol consumption, uncontrolled diabetes or hyperlipidemia, and prior pancreatitis, as these patients might be at greater risk.

References

  1. (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals

Targretin drug interactions

There are 617 drug interactions with Targretin (bexarotene).

Targretin alcohol/food interactions

There are 2 alcohol/food interactions with Targretin (bexarotene).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer